ClinicalTrials.gg

Program

RBD5044

A development code.

Its studies are mostly in Dyslipidemias · Hypertriglyceridemia, led by 2 companies.

Furthest: phase 2, since Jan 22, 20253 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Suzhou Ribo Life Science21 open or runningphase 2since Jan 22, 2025Aug 22, 2022May 31, 2027phase 2 · NCT06797401
Ribotek Biopharmaceuticals (Shandong)11 open or runningphase 2since May 4, 2026May 4, 2026Mar 2027phase 2 · NCT07587788

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 22, 2022First study: phase 1 study in Health VolunteerNew to Suzhou Ribo Life ScienceSuzhou Ribo Life Science · NCT05539651 · 72 enrolled · Australia
  2. Jan 22, 2025Phase 2 study in DyslipidemiasSuzhou Ribo Life Science · NCT06797401 · 120 planned · Poland, Sweden
  3. May 4, 2026Ribotek Biopharmaceuticals (Shandong)'s first study: phase 2 study in HypertriglyceridemiaNew to Ribotek Biopharmaceuticals (Shandong)Ribotek Biopharmaceuticals (Shandong) · NCT07587788 · 40 enrolled · China

Ahead

  1. Mar 2027Primary completion: phase 2 study in HypertriglyceridemiaRibotek Biopharmaceuticals (Shandong) · NCT07587788
  2. May 31, 2027Primary completion: phase 2 study in DyslipidemiasSuzhou Ribo Life Science · NCT06797401

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07587788Hypertriglyceridemia · China2Active, not recruitingRibotek Biopharmaceuticals (Shandong)Mar 202740
NCT06797401Dyslipidemias · Poland, Sweden2RecruitingSuzhou Ribo Life ScienceMay 31, 2027120
NCT05539651Health Volunteer · Australia1CompletedSuzhou Ribo Life ScienceOct 30, 202472

How it is read

Names in the registry

  • “RBD5044”, 3 entries

Codes read as this program: RBD5044.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.